387 related articles for article (PubMed ID: 11046127)
1. 5-hydroxylation of omeprazole by human liver microsomal fractions from Chinese populations related to CYP2C19 gene dose and individual ethnicity.
Shu Y; Wang LS; Xu ZH; He N; Xiao WM; Wang W; Huang SL; Zhou HH
J Pharmacol Exp Ther; 2000 Nov; 295(2):844-51. PubMed ID: 11046127
[TBL] [Abstract][Full Text] [Related]
2. Probing CYP2C19 and CYP3A4 activities in Chinese liver microsomes by quantification of 5-hydroxyomeprazole and omeprazole sulphone.
Shu Y; Wang LS; Xiao WM; Wang W; Huang SL; Zhou HH
Acta Pharmacol Sin; 2000 Aug; 21(8):753-8. PubMed ID: 11501187
[TBL] [Abstract][Full Text] [Related]
3. O-Dealkylation of fluoxetine in relation to CYP2C19 gene dose and involvement of CYP3A4 in human liver microsomes.
Liu ZQ; Zhu B; Tan YF; Tan ZR; Wang LS; Huang SL; Shu Y; Zhou HH
J Pharmacol Exp Ther; 2002 Jan; 300(1):105-11. PubMed ID: 11752104
[TBL] [Abstract][Full Text] [Related]
4. Different contributions of cytochrome P450 2C19 and 3A4 in the oxidation of omeprazole by human liver microsomes: effects of contents of these two forms in individual human samples.
Yamazaki H; Inoue K; Shaw PM; Checovich WJ; Guengerich FP; Shimada T
J Pharmacol Exp Ther; 1997 Nov; 283(2):434-42. PubMed ID: 9353355
[TBL] [Abstract][Full Text] [Related]
5. Human CYP2C19 is a major omeprazole 5-hydroxylase, as demonstrated with recombinant cytochrome P450 enzymes.
Karam WG; Goldstein JA; Lasker JM; Ghanayem BI
Drug Metab Dispos; 1996 Oct; 24(10):1081-7. PubMed ID: 8894508
[TBL] [Abstract][Full Text] [Related]
6. Inhibitory effect of troleandomycin on the metabolism of omeprazole is CYP2C19 genotype-dependent.
He N; Huang SL; Zhu RH; Tan ZR; Liu J; Zhu B; Zhou HH
Xenobiotica; 2003 Feb; 33(2):211-21. PubMed ID: 12623762
[TBL] [Abstract][Full Text] [Related]
7. Characterization of CYP2C19 and CYP2C9 from human liver: respective roles in microsomal tolbutamide, S-mephenytoin, and omeprazole hydroxylations.
Lasker JM; Wester MR; Aramsombatdee E; Raucy JL
Arch Biochem Biophys; 1998 May; 353(1):16-28. PubMed ID: 9578596
[TBL] [Abstract][Full Text] [Related]
8. CYP2B6, CYP3A4, and CYP2C19 are responsible for the in vitro N-demethylation of meperidine in human liver microsomes.
Ramírez J; Innocenti F; Schuetz EG; Flockhart DA; Relling MV; Santucci R; Ratain MJ
Drug Metab Dispos; 2004 Sep; 32(9):930-6. PubMed ID: 15319333
[TBL] [Abstract][Full Text] [Related]
9. Oxidative metabolism of omeprazole in human liver microsomes: cosegregation with S-mephenytoin 4'-hydroxylation.
Chiba K; Kobayashi K; Manabe K; Tani M; Kamataki T; Ishizaki T
J Pharmacol Exp Ther; 1993 Jul; 266(1):52-9. PubMed ID: 8331574
[TBL] [Abstract][Full Text] [Related]
10. Use of omeprazole as a probe drug for CYP2C19 phenotype in Swedish Caucasians: comparison with S-mephenytoin hydroxylation phenotype and CYP2C19 genotype.
Chang M; Dahl ML; Tybring G; Götharson E; Bertilsson L
Pharmacogenetics; 1995 Dec; 5(6):358-63. PubMed ID: 8747407
[TBL] [Abstract][Full Text] [Related]
11. Evidence for involvement of polymorphic CYP2C19 and 2C9 in the N-demethylation of sertraline in human liver microsomes.
Xu ZH; Wang W; Zhao XJ; Huang SL; Zhu B; He N; Shu Y; Liu ZQ; Zhou HH
Br J Clin Pharmacol; 1999 Sep; 48(3):416-23. PubMed ID: 10510155
[TBL] [Abstract][Full Text] [Related]
12. Lack of low Km diazepam N-demethylase in livers of poor metabolizers for S-mephenytoin 4'-hydroxylation.
Yasumori T; Li QH; Yamazoe Y; Ueda M; Tsuzuki T; Kato R
Pharmacogenetics; 1994 Dec; 4(6):323-31. PubMed ID: 7704038
[TBL] [Abstract][Full Text] [Related]
13. CYP2C19 participates in tolbutamide hydroxylation by human liver microsomes.
Wester MR; Lasker JM; Johnson EF; Raucy JL
Drug Metab Dispos; 2000 Mar; 28(3):354-9. PubMed ID: 10681382
[TBL] [Abstract][Full Text] [Related]
14. Identification of cytochromes P450 2C9 and 3A4 as the major catalysts of phenprocoumon hydroxylation in vitro.
Ufer M; Svensson JO; Krausz KW; Gelboin HV; Rane A; Tybring G
Eur J Clin Pharmacol; 2004 May; 60(3):173-82. PubMed ID: 15054565
[TBL] [Abstract][Full Text] [Related]
15. Omeprazole as a CYP2C19 marker in Chinese subjects: assessment of its gene-dose effect and intrasubject variability.
Yin OQ; Tomlinson B; Chow AH; Waye MM; Chow MS
J Clin Pharmacol; 2004 Jun; 44(6):582-9. PubMed ID: 15145965
[TBL] [Abstract][Full Text] [Related]
16. Relationship between CYP2C9 and 2C19 genotypes and tolbutamide methyl hydroxylation and S-mephenytoin 4'-hydroxylation activities in livers of Japanese and Caucasian populations.
Inoue K; Yamazaki H; Imiya K; Akasaka S; Guengerich FP; Shimada T
Pharmacogenetics; 1997 Apr; 7(2):103-13. PubMed ID: 9170147
[TBL] [Abstract][Full Text] [Related]
17. Identification and relative contributions of human cytochrome P450 isoforms involved in the metabolism of glibenclamide and lansoprazole: evaluation of an approach based on the in vitro substrate disappearance rate.
Naritomi Y; Terashita S; Kagayama A
Xenobiotica; 2004 May; 34(5):415-27. PubMed ID: 15370958
[TBL] [Abstract][Full Text] [Related]
18. Catalytic role of cytochrome P4502B6 in the N-demethylation of S-mephenytoin.
Heyn H; White RB; Stevens JC
Drug Metab Dispos; 1996 Sep; 24(9):948-54. PubMed ID: 8886603
[TBL] [Abstract][Full Text] [Related]
19. Identification of CYP3A4 as the major enzyme responsible for 25-hydroxylation of 5beta-cholestane-3alpha,7alpha,12alpha-triol in human liver microsomes.
Furster C; Wikvall K
Biochim Biophys Acta; 1999 Jan; 1437(1):46-52. PubMed ID: 9931427
[TBL] [Abstract][Full Text] [Related]
20. CYP2C19 genotype and S-mephenytoin 4'-hydroxylation phenotype in a Chinese Dai population.
He N; Yan FX; Huang SL; Wang W; Xiao ZS; Liu ZQ; Zhou HH
Eur J Clin Pharmacol; 2002 Apr; 58(1):15-8. PubMed ID: 11956668
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
